<div id="readability-page-1"><p>TD Cowen analyst Stacy Ku maintained a Buy rating on Protara Therapeutics yesterday and set a price target of $30.00. The company’s shares closed today at $6.71.</p><h3>TipRanks Black Friday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for the data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Ku covers the Healthcare sector, focusing on stocks such as LENZ Therapeutics, BioCryst, and KalVista Pharmaceuticals. According to TipRanks, Ku has an average return of <span>8.2%</span> and a 57.89% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Protara Therapeutics with a $25.00 average price target, a 272.58% upside from current levels. In a report released today, Oppenheimer also reiterated a Buy rating on the stock with a $25.00 price target.</p></div>

TARA

<p>TD Cowen analyst Stacy Ku maintained a Buy rating on Protara Therapeutics, setting a price target of $30.00, while the stock closed at $6.71. The consensus among analysts is a Strong Buy with a $25.00 average price target, indicating a 272.58% upside. Oppenheimer also reiterated a Buy rating with a $25.00 target.</p>

Protara Therapeutics (TARA) Receives a Buy from TD Cowen